Preview

Клиническая и экспериментальная тиреоидология

Расширенный поиск

Роль таргетной терапии мультикиназными ингибиторами в лечении резистентного к радиойодтерапии дифференцированного рака щитовидной железы

https://doi.org/10.14341/ket2015225-32

Полный текст:

Аннотация

У 5-15% больных дифференцированным раком щитовидной железы (ДРЩЖ) изначально или в процессе лечения развиваются метастазы, резистентные к терапии радиоактивным йодом, что драматически ухудшает прогноз выживаемости. Другие способы лечения (лучевая терапия, химиотерапия и пр.) также неэффективны. Определенные надежды возлагаются на таргетную терапию мультикиназными ингибиторами, которые селективно блокируют различные онкокиназные молекулярные мишени. В обзоре представлен анализ препаратов этой группы, изучавшихся при радиойодрезистентном ДРЩЖ. Проведен сравнительный анализ эффективности и профиля токсичности двух наиболее перспективных мультикиназных ингибиторов (сорафениб, ленватиниб), успешно прошедших третью фазу клинических исследований и рекомендованных в качестве терапии выбора больным прогрессирующим радиойодрезистентным ДРЩЖ.

Об авторе

Павел Олегович Румянцев
ФГБУ “Эндокринологический научный центр” Минздрава России, Москва
д.м.н., онколог-радиолог, заместитель директора ФГБУ “Эндокринологический научный центр” Минздрава России, Москва, Россия


Список литературы

1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 году. - М.: МНИОИ им. П.А. Герцена; 2015. [Kaprin AD, Starinskii VV, Petrova GV. Zlokachestvennye novoobrazovaniya v Rossii v 2013 godu. Moscow: MNIOI im. P.A. Gertsena; 2015. (In Russ).]

2. Давыдов М.И., Аксесль М.Е. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. - М.: РОНЦ им. Н.Н. Блохина; 2014. [Davydov MI, Aksesl’ ME. Statistika zlokachestvennykh novoobrazovanii v Rossii i stranakh CIS v 2012 g. Moscow: Russian Cancer Research Center n.a. N.N. Blokhin; 2014. (In Russ).]

3. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91(1):313-319. doi: 10.1210/jc.2005-1322.

4. Pitoia F, Bueno F, Cross G. Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancer. Clin Nucl Med. 2014;39(9):784-790. doi: 10.1097/RLU.0000000000000507.

5. Sciuto R, Romano L, Rea S, et al. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol. 2009;20(10):1728-1735. doi: 10.1093/annonc/mdp050.

6. Amin A, Badwey A, El-Fatah S. Differentiated thyroid carcinoma: an analysis of 249 patients undergoing therapy and aftercare at a single institution. Clin Nucl Med. 2014;39(2):142-146. doi: 10.1097/RLU.0000000000000324.

7. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892-2899. doi: 10.1210/jc.2005-2838.

8. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498-505. doi: 10.1210/jc.2005-1534.

9. Biermann M, Pixberg M, Riemann B, et al. Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer - results after 874 patient-years of follow-up in the MSDS-trial. Nuklearmedizin. 2009;48(3):89-98; quiz N15. doi: 10.3413/nukmed-0221.

10. Kwon J, Wu HG, Youn YK, et al. Role of adjuvant postoperative external beam radiotherapy for well differentiated thyroid cancer. Radiat Oncol J. 2013;31(3):162-170. doi: 10.3857/roj.2013.31.3.162.

11. Ye L, Santarpia L, Gagel RF. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev. 2010;31(4):578-599. doi: 10.1210/er.2009-0031.

12. Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22(6):464-468. doi: 10.1016/j.clon.2010.03.014.

13. Matuszczyk A, Petersenn S, Bockisch A, et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res. 2008;40(3):210-213. doi: 10.1055/s-2008-1046781.

14. Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56(9):2155-2160.

15. Thyoird Carcinoma (version 2.2013). NCCN Clinical Practice Guidelines in Oncology. Fort Washington, PA, USA: National Comprehensive Cancer Network; 2013.

16. Droz JP, Schlumberger M, Rougier P, et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori. 1990;76(5):480-483.

17. Kim WG, Kim EY, Kim TY, et al. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr J. 2009;56(1):105-112.

18. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19(5):451-457. doi: 10.1089/thy.2008.0392.

19. Wang KL, Lin LY, Chen PM, Lin HD. Chronic myeloid leukemia after treatment with 131 for thyroid carcinoma. J Chin Med Assoc. 2005;68(5):230-233.

20. Klubo-Gwiezdzinska J, Van Nostrand D, Burman KD, et al. Salivary gland malignancy and radioiodine therapy for thyroid cancer. Thyroid. 2010;20(6):647-651. doi: 10.1089/thy.2009.0466.

21. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89(9): 1638-1644. doi: 10.1038/sj.bjc.6601319.

22. Румянцев П.О., Фомин Д.К., Румянцева У.В. Критерии резистентности высокодифференцированного рака щитовидной железы к терапии радиоактивным йодом. // Опухоли головы и шеи. - 2014. - №3 - С. 4-9. [Rumyantsev PO, Fomin DK, Rumyantseva UV. Criteria of well-differentiated thyroid carcinoma resistance to radioiodine therapy. Opukholi golovy i shei. 2014;(3):4-9.]

23. Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2(5):356-358. doi: 10.1016/S2213-8587(13)70215-8.

24. Brose MS, Smit J, Capdevila J, et al. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther. 2012;12(9):1137-1147. doi: 10.1586/era.12.96.

25. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol. 1999;155(6): 1967-1976. doi: 10.1016/S0002-9440(10)65515-0.

26. Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):656-658. doi: 10.1210/jcem.86.2.7226.

27. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007;14(3):285-294.

28. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454-1457.

29. Wang Y, Hou P, Yu H, et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab. 2007;92(6):2387-2390. doi: 10.1210/jc.2006-2019.

30. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621-630. doi: 10.1056/NEJMoa1406470.

31. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319-328. doi: 10.1016/S0140-6736(14)60421-9.

32. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129-3140. doi: 10.1158/1535-7163.MCT-08-0013.

33. Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1): 97-103. doi: 10.1016/j.canlet.2013.07.007.

34. Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122(3): 664-671. doi: 10.1002/ijc.23131.

35. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708-4713. doi: 10.1200/JCO.2007.15.9566.

36. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897-905. doi: 10.1016/S1470-2045(12)70335-2.

37. Brose MS, Cabanillas ME, Cohen EE. An open-label, multi-center phase 2 study of the BRAF inhibitor vemurafenib in patietns with metastatic or unresectable papillary thryoid cancer positive for the BRAF V600 mutation and resistant to radioactive iodine. Eur J Cancer. 2013;49(suppl 3).

38. Sherman SI, Jarzab B, Caillou B. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol. 2011;29(suppl).

39. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359(1):31-42. doi: 10.1056/NEJMoa075853.

40. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11(10):962-972. doi: 10.1016/S1470-2045(10)70203-5.

41. Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012;18(7):2056-2065. doi: 10.1158/1078-0432.CCR-11-0563.

42. Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010;95(6):2588-2595. doi: 10.1210/jc.2009-1923.

43. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26(29):4714-4719. doi: 10.1200/JCO.2008.16.3279.

44. Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161(6):923-931. doi: 10.1530/EJE-09-0702.

45. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27(10):1675-1684. doi: 10.1200/JCO.2008.18.2717.

46. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21): 5260-5268. doi: 10.1158/1078-0432.CCR-10-0994.

47. Lim SM, Chang H, Yoon MJ, et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol. 2013;24(12):3089-3094.


Для цитирования:


Румянцев П.О. Роль таргетной терапии мультикиназными ингибиторами в лечении резистентного к радиойодтерапии дифференцированного рака щитовидной железы. Клиническая и экспериментальная тиреоидология. 2015;11(2):25-32. https://doi.org/10.14341/ket2015225-32

For citation:


Rumyantsev P.O. The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer. Clinical and experimental thyroidology. 2015;11(2):25-32. (In Russ.) https://doi.org/10.14341/ket2015225-32

Просмотров: 105


ISSN 1995-5472 (Print)
ISSN 2310-3787 (Online)